Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Pituitary Neoplasms × Temozolomide × Clear all

Phase

Status

Withdrawn 1 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 52 Brain Neoplasms 28 Glioma 22 Gliosarcoma 19 Melanoma 18 Astrocytoma 17 Central Nervous System Neoplasms 11 Oligodendroglioma 10 Neoplasms 9 Neoplasm Metastasis 8 Recurrence 6 Carcinoma, Non-Small-Cell Lung 5 Neuroblastoma 4 Lymphoma 4 Ependymoma 4 Diffuse Intrinsic Pontine Glioma 3 Breast Neoplasms 3 Sarcoma, Ewing 2 Neurologic Manifestations 2 Neuroectodermal Tumors, Primitive 2 Neoplasms, Second Primary 2 Meningeal Carcinomatosis 2 Medulloblastoma 2 Bone Neoplasms 2 Urinary Bladder Neoplasms 1 Thrombocytopenia 1 Tetanus 1 Spinal Cord Neoplasms 1 Solid Tumors 1 Small Cell Lung Cancer Recurrent 1

Interventions

pasireotide 3 lanreotide 1 Temozolomide 1 Rosiglitazone 1 Pafolacianine 1 Endoscopic Mucosal Resection 1 Dexamethasone 1 Capecitabine 1 Calcium Dobesilate 1 Cabergoline 1 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03930771 2022-08-09

TMZ-Cap

Weill Medical College of Cornell University

Phase 2 Terminated

1 enrolled 8 charts

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡